Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Debled

Showing results (91-100 of 100) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 100 results.
Breast (Edinburgh, Scotland)|December 11, 2020
Impact of body mass index on overall survival in patients with metastatic breast cancerKhalil Saleh, Matthieu Carton, Véronique Dieras, et al.
Clinical Pharmacology and Therapeutics|August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD TrialEnora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
British Journal of Cancer|November 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohortAmélie Darlix, Guillaume Louvel, Julien Fraisse, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohortElisa Gobbini, Monia Ezzalfani, Véronique Dieras, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2020
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016Elise Deluche, Alison Antoine, Thomas Bachelot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast CancerThomas Bachelot, Paul Cottu, Sylvie Chabaud, et al.
Nature Medicine|January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trialThomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
Bulletin Du Cancer|July 31, 2016
[Breast cancer screening: On our way to the future]Suzette Delaloge, Thomas Bachelot, François-Clément Bidard, et al.
Bulletin Du Cancer|December 29, 2016
[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]]Suzette Delaloge, Thomas Bachelot, François-Clément Bidard, et al.
The New England Journal of Medicine|June 5, 2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast CancerPrudence A Francis, Olivia Pagani, Gini F Fleming, et al.
Pageof 10

Showing results (91-100 of 100) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 100 results.
Breast (Edinburgh, Scotland)|December 11, 2020
Impact of body mass index on overall survival in patients with metastatic breast cancerKhalil Saleh, Matthieu Carton, Véronique Dieras, et al.
Clinical Pharmacology and Therapeutics|August 24, 2025
Association Between Daily Timing of Everolimus and Survival in High-Risk HR+/HER2- Early Breast Cancer: A Sub-Analysis of the UCBG-UNIRAD TrialEnora Laas, Anne-Sophie Hamy, Thomas Bachelot, et al.
British Journal of Cancer|November 14, 2019
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohortAmélie Darlix, Guillaume Louvel, Julien Fraisse, et al.
European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohortElisa Gobbini, Monia Ezzalfani, Véronique Dieras, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2020
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016Elise Deluche, Alison Antoine, Thomas Bachelot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast CancerThomas Bachelot, Paul Cottu, Sylvie Chabaud, et al.
Nature Medicine|January 19, 2021
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trialThomas Bachelot, Thomas Filleron, Ivan Bieche, et al.
Bulletin Du Cancer|July 31, 2016
[Breast cancer screening: On our way to the future]Suzette Delaloge, Thomas Bachelot, François-Clément Bidard, et al.
Bulletin Du Cancer|December 29, 2016
[Erratum to: "Breast cancer screening: On our way to the future" [Bull. Cancer 103 (2016) 753-763]]Suzette Delaloge, Thomas Bachelot, François-Clément Bidard, et al.
The New England Journal of Medicine|June 5, 2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast CancerPrudence A Francis, Olivia Pagani, Gini F Fleming, et al.
Pageof 10